Based on the National Health and Morbidity Survey (NHMS) 2023 report, around 54.4 per cent of Malaysian adults were ...

Elaborating on this weight-loss innovation, Dr Nik Ritza Kosai said there are various types of IGBs but only the Allurion balloon does not require an endoscopy for insertion. “All a patient has to do ...

NATICK, Mass., January 08, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug ...

Allurion Technologies (ALUR) announced topline results from the AUDACITY FDA pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial is an open-label ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a biotechnology firm focused on obesity treatment, announced the topline results from its AUDACITY FDA pivotal trial, which evaluated the ...